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Abstract
Background HMG-CoA reductase inhibitors (statins) are
the first-choice therapy for primary prevention of cardio-
vascular disease. Some maintain that statins cause adverse
musculoskeletal outcomes in highly active individuals, but
few studies have examined the effects of statins on exer-
cise-related injuries.
Objective We sought to compare the prevalence of exercise-
related injuries between runners who do or do not use statins.
Methods Amateur runners (n = 4460) completed an
extensive online questionnaire on their exercise patterns
and health status. Participants replied to questions on the
prevalence of exercise-related injuries in the previous year.
Injuries were divided into general injuries, tendon- and
ligament-related injuries, and muscle-related injuries. Par-
ticipants were also queried about statin use: the type of
statin, statin dose, and duration of treatment. Runners were
divided into statin users, non-statin users with hyperc-
holesterolemia, and controls for analysis.
Results The crude odds ratios (ORs) for injuries, tendon-
or ligament-related injuries, and muscle-related injuries in
statin users compared with controls were 1.14 (95% con-
fidence interval [CI] 0.79–1.66), 1.10 (95% CI 0.71–1.72),
and 1.15 (95% CI 0.69–1.91), respectively. After adjust-
ment for age, sex, body mass index (BMI), and metabolic
equivalent of task (MET) h/week of exercise, the ORs were
1.11 (95% CI 0.76–1.62), 1.06 (95% CI 0.68–1.66), and
0.98 (95% CI 0.58–1.64), respectively. Similar effect
measures were found when comparing non-statin users
with hypercholesterolemia and controls.
Conclusion We did not find an association between statin
use and the prevalence of exercise-related injuries or ten-
don-, ligament-, and muscle-related injuries. Runners
receiving statins should continue normal physical activity
without concern for increased risk of injuries.
Key Points
There is no evidence of an association between statin
use and the prevalence of exercise-related injuries in
amateur runners.
Runners receiving statins should continue normal
physical activity without concern for increased risk
of injuries as statin use and exercise training both
improve their cardiovascular risk profile.
1 Introduction
HMG-CoA reductase inhibitors (statins) are the first-choice
therapy for the primary prevention of cardiovascular dis-
ease (CVD) since they reduce all-cause and cardiovascular
mortality and the risk of non-fatal cardiovascular events
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[1, 2]. Clinical trials examining the efficacy of statins sel-
dom report statin-associated adverse events, and a meta-
analysis did not find an increased risk of myopathy, fatigue,
muscle aches, or rhabdomyolysis or an increase in creatine
kinase concentrations[10 9 the upper limit of normal in
the statin arm compared with the placebo arm [3]. How-
ever, statin-associated side effects might be incompletely
reported, and randomized trials may lack the right study
design or be underpowered to detect musculoskeletal side
effects [4].
A meta-analysis found a statistically significant decrease
in absolute risk difference in myopathic symptoms (risk
difference –0.4%; 95% confidence interval [CI] –0.5 to
–0.3) and muscle aches (risk difference –0.6% [95% CI
–1.1 to –0.1]) with low- versus high-intensity statin ther-
apy. However, only 57% of the myopathic symptoms and
16% of the muscle aches were dose related [3]. A large
observational study including 46,249 individuals showed a
19% increased risk of musculoskeletal disorders (odds ratio
[OR] 1.19; 95% CI 1.08–1.30) in statin users compared
with age-, sex-, and comorbidity-matched controls.
Specifically, arthropathies, musculoskeletal injuries, and
pain are more commonly observed in statin users than in
matched controls [5]. An additional observational study
revealed that statin use in individuals without arthritis is
associated with a significantly higher prevalence of mus-
culoskeletal pain in any region, the lower back, and the
lower extremities (prevalence ratios 1.33 [95% CI
1.06–1.67]; 1.47 [95% CI 1.02–2.13]; 1.59 [95% CI
1.12–2.22], respectively) [6]. Additionally, case reports
suggest that statins may cause tendon injuries, including
tendinitis and tendon rupture [7, 8]. These observations
suggest that muscular and tendinous injuries may be more
prevalent in statin users. There is also evidence that statin-
related side effects are more prevalent in physically active
individuals. For example, the PRIMO (PRedIction of
Muscular Risk in Observational Conditions) study reported
myalgia in 10.5% of subjects overall, but the rate was
14.7% in patients practicing an ‘‘intense form of sport’’ [9].
Statin intolerance has also been reported in 22 professional
athletes with low-density lipoprotein receptor defects, only
six of whom could tolerate statins despite multiple attempts
with the five statins available at that time [10]. Creatine
kinase levels 24 h after a 42-km footrace were 38% higher
in amateur runners receiving statins than in non-statin-
treated controls [11]. Whether physically active individuals
receiving statins are more likely to develop exercise-related
injuries is unknown.
The aim of this study was to compare the prevalence of
exercise-related injuries between statin-using runners and
runners not using these medications. For this purpose, we
studied participants in the 15-km ‘Seven Hills Run’ in
Nijmegen, one of the largest road running races in the
Netherlands. We hypothesized that statin-using runners
would demonstrate an increased risk for muscle-, tendon-,
and ligament-related sport injuries.
2 Method
This cross-sectional analysis was performed as part of the
Nijmegen Exercise Study (http://www.runningresearch.nl).
This study is a large prospective study examining the
impact of physical activity on health, quality of life, and
the development and progression of chronic diseases.
Amateur athletes participating in the Seven Hills Run were
recruited by newsletter and internet advertisements. All
Dutch-speaking adults participating in the 2014 Seven
Hills Run were eligible to respond to the online question-
naire. Potential subjects provided written informed consent
before they could access the online questionnaire, as
approved by The Local Committee on Research Involving
Human Subjects of the region Arnhem and Nijmegen, the
Netherlands. Participants were asked about their general
characteristics, lifestyle, medical history, and medication
use.
2.1 Questionnaire
The online questionnaire inquired in detail about general
characteristics, lifestyle factors, medical history, and
medication use. General characteristics included age, sex,
weight, and height. Lifestyle factors were the average
number of sleeping hours per night and the amount of
habitual physical activity. The latter was estimated using
the SQUASH questionnaire [12], which is divided into
different domains (occupation, leisure time, household,
and transportation) and asked participants about the
duration and intensity of their weekly activities over past
months. Weekly activities were converted to the average
amount of metabolic equivalent of task (MET) hours per
week spent on exercise. MET hours were calculated by
multiplying the MET values of each sports activity by
exercise duration (in h) [13]. The medical history con-
tained questions about physician-made diagnoses of CVD,
hypertension, hypercholesterolemia, and diabetes mellitus
as well as the types and doses of medication used in the
past year.
2.2 Statin Use
Participants were asked whether they used atorvastatin
(Lipitor or Atorab), fluvastatin (Lescol), pravastatin
(Selektine), rosuvastatin (Crestor), simvastatin (Zocor),
and the combination drugs ezetimibe/simvastatin (Inegy)
and pravastatin/fenofibrate (Pravafenix) or any other
E. A. Bakker et al.
123
cholesterol-lowering drugs. If participants used statins or
combination drugs, they were classified as statin users.
Participants with normal cholesterol values were classified
as controls. Non-statin users with physician-diagnosed
hypercholesterolemia were classified as non-statin users
with hypercholesterolemia. Information on the intake fre-
quency, statin dose, and duration of use was collected. To
quantify a potential dose–response relationship, the dose of
drug was standardized to ‘atorvastatin’ equivalence in
which 1 equivalent = rosuvastatin 2.5 mg = atorvastatin
5 mg = simvastatin 10 mg = lovastatin 20 mg = pravas-
tatin 20 mg = fluvastatin 40 mg [14, 15].
2.3 Exercise-Related Injuries
Participants were questioned about their injuries in the
previous year. If an injury had occurred, participants were
asked to specify whether these injuries concerned muscle
injuries (e.g., hamstring injury, back complaints, golfer’s
elbow, calf strains), tendon or ligament injuries (e.g.,
Achilles tendon injuries, ankle sprain, groin injury, ili-
otibial band syndrome, knee ligaments injuries, plantar
fasciitis, tennis elbow, or other tendon injuries), or other
types of injuries (e.g., shin splint, hip injury, chon-
dropathy, bursitis). Participants were also asked to report
the duration of their injury and their need for medical
help.
2.4 Data Analysis
Differences in characteristics between statin users, non-
statin users with hypercholesterolemia, and controls were
assessed by descriptive statistics. Continuous variables are
reported as mean ± standard deviation or median with
25th and 75th quartiles (Q25–Q75). Differences were tested
with one-way analysis of variance (ANOVA) for normally
distributed variables and by Kruskal–Wallis one-way
ANOVA for variables that were not normally distributed.
Categorical data were reported in proportions and tested
with the chi-squared test.
To evaluate the relation between statin use and sport
injuries, logistic regression was performed to determine
ORs and adjust for possible confounders. Variables where
classified as confounders if they satisfied the criteria for
confounding [16]. Adjusted ORs were calculated with a
95% CI for the occurrence of sport injuries, tendon- or
ligament-related injuries, and muscle-related injuries, for
statin users and non-statin users with hypercholesterolemia
compared with controls. All statistical analyses were per-
formed using SPSS 20.0 (SPSS, Chicago, IL, USA) soft-
ware. P values of \0.05 were considered statistically
significant.
3 Results
3.1 Study Population
In total, 4585 participants completed the questionnaire.
After exclusion of participants with missing data, 4460
cases (97%) were available for analysis. In total, 378
runners reported a diagnosis of hypercholesterolemia; 117
of these respondents used statins (Fig. 1).
Compared with participants in the other two groups,
statin users had a slightly higher body mass index (BMI),
were a few years older, and were more likely to be men (all
p\ 0.001). CVD, hypertension, and diabetes mellitus were
more prevalent in statin users than in the other two groups
(p\ 0.001). Lifestyle factors, such as running distance per
training, and average number of sleeping hours per night,
did not differ between the three groups (Table 1). MET
hours spent per week on exercise was significantly higher
in non-statin users with hypercholesterolemia compared to
controls.
3.2 Statin Use and Injury Prevalence
Simvastatin (57%) and atorvastatin (25%) were the most
frequently used statins. The median potency of statin used
by the participants was 4 (Q25 2–Q75 4). The duration of
statin use was 0–2, 3–9, and[10 years in 30, 39, and 22%
of the cases, respectively (Table 2).
Of the statin users, 41% reported an injury in the past
year: tendon- or ligament-related sport injuries 22%,
muscle-related injuries 15%, and other injuries 13%. The
majority (30%) of the statin users reported one injury and
10% reported two injuries. Injury duration and the need for
medical help did not differ between the three groups.
Compared with statin users, injury prevalence was slightly
but insignificantly lower in non-statin users with hyperc-
holesterolemia (40%) and controls (38%) (Table 3).
3.3 Injury Risk Analyses
The crude ORs for statin users were 1.14 (95% CI
0.79–1.66) for injuries, 1.10 (95% CI 0.71–1.72) for ten-
don- or ligament-related injuries, and 1.15 (95% CI
0.69–1.91) for muscle-related injuries compared with
controls (Fig. 2). Even after adjustment for age, sex, BMI,
and MET hours per week, the ORs for injuries (OR 1.11
[95% CI 0.76–1.62]), tendon- or ligament-related injuries
(OR 1.06 [95% CI 0.68–1.66]), and muscle-related injuries
(OR 0.98 [95% CI 0.58–1.64]) did not differ between statin
users and controls. The risk for exercise-related injuries
was also comparable between statin users and non-statin
users with hypercholesterolemia. Sub-analysis for the
Statin Use and Exercise-Related Injuries
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Fig. 1 Flowchart of the
enrolment of the study
population. BMI body mass
index, MET metabolic
equivalent of task
Table 1 Characterisation of 4460 participants divided into three groups relating to statin use and the presence of hypercholesterolemia
Statin users
(N = 117)
Non-statin users with
hypercholesterolemia (N = 261)
Controls
(N = 4082)
p value
Age (years) 56 ± 8 54 ± 9 46 ± 12 \0.001
Sex (male) 94 (80) 198 (76) 2337 (57) \0.001
BMI (kg/m2) 24.6 ± 2.4 23.9 ± 3.5 23.2 ± 2.7 \0.001
Exercise (MET h/week) 32 (18–50) 34 (24–48) 32 (20–48) 0.042
Running distance per training session (km)a 10 (7–11) 10 (8–11) 10 (8–11) 0.465
Sleeping hours (per night) 7.0 ± 0.9 7.0 ± 0.9 7.0 ± 0.8 0.437
General health
CVDb 35 (30) 26 (10) 128 (3) \0.001
Hypertension 47 (40) 65 (25) 365 (9) \0.001
DM 14 (12) 6 (2) 38 (1) \0.001
Injuries
Total injuries 48 (41) 105 (40) 1544 (38) 0.590
Tendon/ligaments 26 (22) 54 (21) 840 (21) 0.910
Muscle 18 (15) 49 (19) 559 (14) 0.066
Other 15 (13) 28 (11) 477 (12) 0.829
Injury duration (weeks) 6 (3–12) 5 (2–10) 5 (3–10) 0.56
Need for medical help 36 (31) 77 (30) 1076 (26) 0.570
Data are presented as mean ± SD, median (Q25–Q75), or n (%)
BMI body mass index, CVD cardiovascular disease, DM diabetes mellitus, MET metabolic equivalent of task
a 1273 (29%) are missing values
b Myocardial infarction, heart failure, stroke, thrombosis, and atrial fibrillation
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potency of statin use in atorvastatin equivalents did not
show a significant dose–response relation for injuries in
general (OR 1.06 [95% CI 0.96–1.18] per equivalent),
tendon- or ligament-related injuries (OR 1.05 [95% CI
0.93–1.17] per equivalent), or muscle-related injuries (OR
1.02 [95% CI 0.89–1.16] per equivalent). Furthermore, we
found no effect of the duration of statin use on the preva-
lence of injuries.
4 Discussion
The present study investigated whether statin use was
associated with the prevalence of exercise-related injuries
in a large and heterogeneous cohort of amateur runners
(n = 4460). Injuries were highly prevalent (38%) among
participants, but we did not find a higher injury risk in
statin-using runners versus control runners (OR 1.14 [95%
CI 0.79–1.66]). Sub-analyses revealed a similar lack of
relationship between tendon-, ligament-, and muscle-re-
lated injuries. There was also no significant association
between the potency of statin used or treatment duration
and injury risk. These findings demonstrate that the risk for
Table 2 Quantification of the different types of statins, the effective dose,
and the duration of statin use in participants using statins (n = 117)
Characteristics Prevalencea
Statin type
Atorvastatin (Lipitor or Atorab) 29 (25)
Ezetimibe/simvastatin (Inegy) 2 (2)
Fluvastatin (Lescol) 2 (2)
Pravastatin (Selektine) 4 (3)
Pravastatin/fenofibrate (Pravafenix) 1 (1)
Rosuvastatin (Crestor) 12 (10)
Simvastatin (Zocor) 67 (57)
Median expected potency of atorvastatin
equivalentsb
4 (Q25 2–Q75
4)
Duration of usage (years)
0–2 34 (29)
3–9 45 (39)
C10 27 (23)
Q25 25th quartile, Q75 75th quartile
a Data are presented as n (%) unless otherwise indicated
b One atorvastatin equivalent (5 mg) = rosuvastatin 2.5 mg = sim-
vastatin 10 mg = lovastatin 20 mg = pravastatin 20 mg = fluvas-
tatin 40 mg
Table 3 Quantification of 1697 sport injuries in the three study groups
Statin users
(N = 117)
Non-statin users with
hypercholesterolemia (N = 261)
Controls
(N = 4082)
Sport injuries 48 (41) 105 (40) 1544 (38)
Tendon or ligaments 26 (22) 54 (21) 840 (41)
Achilles tendon 13 (11) 23 (9) 331 (8)
Ankle sprain 1 (1) 7 (3) 125 (3)
Groin injury 4 (3) 2 (1) 65 (2)
Iliotibial band syndrome 5 (4) 3 (1) 128 (3)
Knee ligaments 2 (2) 7 (3) 81 (2)
Plantar fasciitis 2 (2) 8 (3) 83 (2)
Tendon injury 2 (2) 7 (3) 92 (2)
Tennis elbow 0 (0) 0 (0) 14 (0)
Other 1 (2) 7 (3) 107 (3)
Muscles 18 (15) 49 (19) 559 (14)
Golfer’s elbow 0 (0) 1 (0) 3 (0)
Hamstrings 7 (6) 14 (5) 193 (5)
Back complaints 6 (5) 11 (4) 185 (5)
Calf strains 4 (3) 9 (3) 59 (1)
Other 1 (1) 8 (3) 105 (3)
Other 15 (13) 28 (11) 477 (12)
Shin splint 1 (1) 7 (3) 82 (2)
Hip injury 4 (3) 5 (2) 127 (3)
Chondropathy 7 (6) 7 (3) 124 (3)
Bursitis 1 (1) 5 (2) 41 (1)
Other 3 (6) 10 (10) 160 (10)
Data are presented as n (%)
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exercise-related injuries is similar between amateur runners
regardless of statin use.
A total of 378 amateur runners with a diagnosis of
hypercholesterolemia participated in the present study. As
expected [17], participants with hypercholesterolemia had
a worse cardiovascular risk profile than controls, which
justifies the prescription of statins (Table 1). Surprisingly,
only 31% (n = 117) of the participants with hypercholes-
terolemia reported using statins. Physically active low-risk
individuals may have received lifestyle advice only instead
of immediately commencing statin treatment for primary
prevention [18]. Alternatively, these runners may not have
tolerated statins and discontinued statin therapy. Statin
users demonstrated a significantly higher BMI and preva-
lence of CVD, hypertension, and diabetes mellitus than
non-statin users with hypercholesterolemia. These obser-
vations demonstrate that statin therapy was appropriately
used more often in higher-risk individuals.
Contrary to our hypothesis, statin use did not increase
injury risk in amateur runners. The 1-year injury preva-
lence (38%) with statin use was similar to that observed by
others (35%) [19], but crude and adjusted ORs demon-
strated no significant difference in injury risk across our
three study groups. These findings contrast with data from
a large American study (n = 46,249) that included active-
duty soldiers, veterans, and their family members [5].
Statin users reported an increased risk (OR 1.13 [95% CI
1.05–1.21]) for musculoskeletal injuries during 5 years of
follow-up. However, the incidence of musculoskeletal
injuries is known to be higher in soldiers than in the general
population [20–22] and may also originate from non-ex-
ercise activities (e.g., changes in psychological and work
demands, increasing rates of depression, and increased
symptom awareness and reporting). Our findings do not
confirm that statin use increases the prevalence of muscu-
loskeletal injuries; however, the sample size of our study is
considerably smaller, which may reduce the statistical
power, and exercise amount and intensity was likely
greater in the soldiers. A high volume of exercise exposure
may be a risk factor for statin-associated symptoms
because statin-associated musculoskeletal complaints have
previously been reported in highly active individuals [9]
and professional athletes [10]. Our cohort was quite active
and reported a median exercise volume of 32 MET hours
per week, which is equivalent to *3 times the World
Health Organization (WHO) recommendations for 150
min/week of moderate-intensity activities [23] but possibly
not active enough to produce a higher rate of complaints.
Fig. 2 Crude and adjusted odds ratios of total injuries, tendon- or
ligament-related injuries, and muscle-related injuries. BMI body mass
index, CI confidence interval, HC hypercholesterolemia, MET
metabolic equivalent of task, OR odds ratio. *Adjusted for age, sex,
BMI, and MET hours per week
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4.1 Clinical Relevance
We found no evidence for statin-induced exercise-related
injuries in a large and heterogeneous cohort of recreational
athletes. This observation supports the prescription of sta-
tins for primary and secondary prevention of adverse car-
diovascular outcomes in physically active individuals with
increased cardiovascular risk. In fact, the combination of
statin therapy and physical activity yields greater risk
reductions for all-cause mortality compared with statin use
or physical activity independently [24]. Furthermore,
another study found no detrimental effects of statin use on
aerobic exercise performance among middle-aged athletes
[25]. These findings emphasize that amateur athletes
should not fear an increased risk of statin-associated side
effects.
4.2 Limitations
There are limitations to the present report. We examined a
large population-based cohort of recreational runners, but
this cohort included only 117 statin users. We noted that
69% of runners reported having been diagnosed with
hypercholesterolemia but were not receiving statins. This
raises the possibility that these runners had discontinued
statin use because of side effects, but we did not query our
cohort about statin discontinuation. Another explanation
for the absence of an effect might be explained by runners
who stopped running because of statin-induced injuries and
therefore did not participate in the Seven Hills Run. This
might cause selection bias, which underestimates the true
effect. However, this study examined injury prevalence
during the year before participation in the study. Our
results also depend entirely on self-reported exercise habits
and medical diagnoses, which were not confirmed by
examining medical records. Further, we assumed that
reported injuries were exercise related. Despite these lim-
itations, this study is, to our knowledge, the first to directly
examine the relationship between vigorous exercise such as
running and possible statin-associated musculoskeletal side
effects.
5 Conclusion
We did not find an association between statin use in run-
ners and injuries or tendon-, ligament-, and muscle-related
injuries. Given the lower risk of cardiovascular events in
individuals who are both using statins and have greater
cardiorespiratory fitness, runners receiving statins should
continue both statin use and their physical activity without
undue concern for the risk of injury.
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